{"id":169467,"date":"2026-08-15T20:56:20","date_gmt":"2026-08-15T20:56:20","guid":{"rendered":"https:\/\/www.europesays.com\/canada\/169467\/"},"modified":"2026-08-15T20:56:20","modified_gmt":"2026-08-15T20:56:20","slug":"medtronic-mdt-wins-health-canada-nod-for-affera-heart-rhythm-system","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/canada\/169467\/","title":{"rendered":"Medtronic (MDT) Wins Health Canada Nod For Affera Heart Rhythm System"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. <\/p>\n

Medtronic (NYSE:MDT) has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter for the treatment of atrial fibrillation and atrial flutter. <\/p>\n

The licence allows commercial use of Medtronic’s combined pulse field and radiofrequency ablation technologies across Canada. <\/p>\n

The Affera system provides physicians with an all-in-one mapping and ablation platform aimed at supporting procedural efficiency and patient care. <\/p>\n

The approval marks a milestone for Medtronic’s Cardiac Ablation Solutions division in the global atrial fibrillation treatment market. <\/p>\n

This kind of regulatory progress is only one slice of the opportunity in tech enabled cardiac care, so it can be worth looking more broadly at other stocks linked to similar healthcare trends through 44 healthcare AI stocks<\/a>. <\/p>\n

\"NYSE:MDT<\/a> NYSE:MDT Earnings & Revenue Growth as at Aug 2026 <\/p>\n

Medtronic is a US based medical equipment company with a market cap of about $115.9b that develops and sells device based therapies to healthcare systems and clinicians globally. The Affera platform is part of this broader focus on treating cardiac conditions through interventional devices rather than drugs. <\/p>\n

Beyond the headline: 0 risks and 5 things going right for Medtronic that every investor should see.<\/a> <\/p>\n

How the Affera approval feeds into the Medtronic cardiac ablation story <\/p>\n

The core Medtronic Narrative is that a deeper portfolio in device based therapies and digital health can shift more cardiac procedures onto its own platforms, while operational changes aim to support earnings over time. <\/p>\n

“Strengthening the innovation pipeline (e.g., Sphere-360, new carotid and thrombectomy devices, next-gen Ardian) combined with an enhanced governance… ” <\/p>\n

Read the full Medtronic narrative<\/a> to see the case behind these numbers<\/a> <\/p>\n

Health Canada approval for Affera and the Sphere-9 catheter sits squarely in that pipeline thesis. It adds another pulse field ablation option alongside PulseSelect and extends the Cardiac Ablation Solutions story from Europe and the US into Canada, where Medtronic now competes more directly with Abbott and Boston Scientific for complex atrial fibrillation work. <\/p>\n

On the bear side, this launch also highlights the execution risk the Narrative flags. Medtronic is running multiple high spend ramps in CAS, robotics and diabetes, so investors still need proof that Affera usage can scale without putting fresh pressure on margins or being slowed by training and workflow change in Canadian centers. <\/p>\n

For investors, this approval only really matters in the context of which Medtronic story you back, and how far Affera fits that version of the future for the company. To ensure you’re always in the loop on how the latest news impacts the investment narrative for Medtronic, head to the community page for Medtronic<\/a> to never miss an update on the top community narratives. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include MDT<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":169468,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[54189,1578,54190,17,54191,1855,54188],"class_list":["post-169467","post","type-post","status-publish","format-standard","has-post-thumbnail","category-canada","tag-affera","tag-atrial-fibrillation","tag-atrial-flutter","tag-canada","tag-cardiac-ablation","tag-health-canada","tag-medtronic"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/169467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/comments?post=169467"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/posts\/169467\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media\/169468"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/media?parent=169467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/categories?post=169467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/canada\/wp-json\/wp\/v2\/tags?post=169467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}